Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma

Translational Oncology

Yan Wang¹  Jianming Ying²  Haiyan Xu³  Junling Li⁴  Lu Yang⁴  Guangjian Yang⁴  Jing Zhang⁵  Lei Guo⁵  Xin Li⁵  Lijia Wu⁶  Beibei Mao⁶  Xinying Shi⁶  Ying Yang⁶  Jiyu Wei⁶  Henghui Zhang⁶  Yane Song⁶ 

[1] Corresponding author at: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.;Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Genecast Precision Medicine Technology Institute, Beijing 100021, China;

关键词: Stage IA;    Lung adenocarcinoma;    Relapse;    Tumour immunity;    Molecular alteration;   

DOI  :  

来源: DOAJ

【 摘 要 】

Patients with early-stage non-small cell lung cancer (NSCLC), even stage IA, are at substantial risk of relapse and death. We explored the distinct features of molecular alterations and immune-related gene expression in Formalin-fixed paraffin-embedded (FFPE) samples from 25 relapsed patients compared with 25 non-relapsed patients through using whole-exome sequencing and an immune oncology panel RNA sequencing platform. Results showed that the chemokine, cytolytic activity and tumour-associated antigen gene signatures exhibited significantly higher expression in non-relapsed tumours from stage IA lung adenocarcinoma (LUAD) than that in relapsed tumours. Besides, Kaplan–Meier survival analysis revealed that the gene signatures of chemokines and tumour-associated antigens were significantly associated with the patients’ disease-free survival (DFS), indicating their prognostic value in early-stage LUAD. Cytolytic activity displayed a similar trend but failed to reach statistical significance. These findings revealed a weakened immune phenotype in relapsed tumours and provide valuable information for improving the treatment management of these high-risk patients. Due to the overall small patient number in this study, these differences should be further validated in a larger cohort.

【 授权许可】

Unknown